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Pneumonia Hospitalizations Among Young Children Before and After 
Introduction of Pneumococcal Conjugate Vaccine — United States, 1997–2006
Streptococcus pneumoniae is the leading bacterial cause of 
community-acquired pneumonia hospitalizations and an 
important cause of bacteremia and meningitis, especially 
among young children and older adults (1,2). A 7-valent 
pneumococcal conjugate vaccine (PCV7) was licensed and 
the Advisory Committee on Immunization Practices formu-
lated recommendations for its use in infants and children in 
February 2000 (2). Vaccination coverage rapidly increased 
during the second half of 2000, in part through funding by 
CDC’s Vaccines for Children program. Subsequently, active 
population- and laboratory-based surveillance demonstrated 
substantial reductions in invasive pneumococcal disease (IPD) 
among children and adults (3). In addition, decreases in hospi-
talizations and ambulatory-care visits for all-cause pneumonia 
also were reported (4,5). To gauge whether the effects of PCV7 
on reducing pneumonia continue, CDC is monitoring pneu-
monia hospitalizations by using data from the Nationwide 
Inpatient Sample. This report provides an update for 2005 
and 2006, the most recent years for which information is 
available. In 2005 and 2006, the incidence rates for all-cause 
pneumonia hospitalizations among children aged <2 years 
were 9.1 per 1,000 and 8.1 per 1,000, respectively. In 2006, 
the rate for all-cause pneumonia among children aged <2 years 
was approximately 35% lower than during 1997–1999. Most 
of this decrease occurred soon after the vaccine was licensed in 
2000, and the rates have remained relatively stable since then. 
The rate for all-cause pneumonia among children aged 2–4 
years did not change after PCV7 licensure and has remained 
stable. Continued monitoring of pneumonia-related hospi-
talizations among children is needed to track the effects of 
pneumococcal immunization programs.
The Nationwide Inpatient Sample contains data on inpatient 
stays from states that participate in the Healthcare Cost and 
Utilization Project, sponsored by the Agency for Healthcare 
Research and Quality. The project is a stratified probability 
sample of U.S. acute-care hospitals and the largest all-payer 
inpatient-care database available in the United States. In 2006, 
this database recorded information from approximately 8 mil-
lion hospitalizations (approximately 20% of all U.S. hospital-
izations) from 1,045 hospitals in 38 states. Data are weighted 
to generate national estimates while accounting for complex 
sampling design (6). For this analysis, all-cause pneumonia 
hospitalization was defined as a record in which International 
Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes 480–486 (pneumonia) or 487.0 (influenza 
with pneumonia) were assigned as the primary diagnosis.
Trends in hospitalizations for nonpneumonia acute respira-
tory illness (ARI) also were evaluated to assess the possibility 
that, after PCV7 introduction, practitioners were less likely 
to assign a pneumonia code for respiratory conditions in a 
vaccinated child and more likely to make other respiratory 
diagnoses. A nonpneumonia ARI hospitalization was defined 
as a record with any of the following ICD-9-CM codes 
assigned as the primary diagnosis: 381–383 (otitis media and 
mastoiditis), 460–466 (acute respiratory infections, including 
acute bronchitis, bronchiolitis, acute nasopharyngitis, sinusitis, 
pharyngitis, tonsillitis, laryngitis, tracheitis, and other acute 
upper respiratory infections), 487 (influenza, excluding 487.0), 
490 (bronchitis), 491 (chronic bronchitis), or 493 (asthma). 
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Some of these diagnoses, such as asthma, bronchiolitis, or 
acute bronchitis generally are not considered to be caused by 
S. pneumoniae.
Hospitalization rates among children aged <2 years and 2–4 
years were calculated by dividing the total number of yearly 
hospitalizations by age-specific population denominators from 
U.S. census data. Baseline rates before introduction of PCV7 
were defined as the average annualized rates during 1997–1999; 
incidence rate ratios (RRs) were calculated by dividing esti-
mated rates for 2006 by the baseline rates. Point estimates 
and 95% confidence intervals (CIs) were calculated using 
outcome-specific Poisson regression models that accounted 
for the Nationwide Inpatient Sample sampling design. Rate 
differences between baseline and 2006 rates were multiplied 
by age-specific census data to estimate changes in the absolute 
number of hospitalizations during 2006. To examine changes in 
the distribution of causes of hospitalization after introduction 
of PCV7, the proportion of all nonbirth-related hospitaliza-
tions that were coded as pneumonia and nonpneumonia ARI 
among children aged <2 years during 1997–1999 and 2006 
were calculated.
In 2005, a total of 74,559 children aged <2 years were hos-
pitalized in the United States for all-cause pneumonia, and 
67,430 were hospitalized in 2006, accounting for approxi-
mately 8% of yearly nonbirth-related hospitalizations in this 
age group. The rates of all-cause pneumonia hospitalization per 
1,000 children aged <2 years were 9.1 in 2005 and 8.1 in 2006. 
Although the rate of all-cause pneumonia in 2005 was higher 
than in 2004 (8.0), this increase was not statistically significant. 
The 2005 and 2006 rates were 27% and 35% lower than the 
baseline rate of 12.5 per 1,000 (Table). For 2006, the rate 
reduction represented an estimated 36,300 fewer pneumonia 
hospitalizations among children aged <2 years during 2006, 
compared with the average annual number of hospitalizations 
during 1997–1999. Among children aged 2–4 years, the rate 
of all-cause pneumonia hospitalization did not change signifi-
cantly during the study years (Table, Figure).
Among children aged <2 years, the rate of nonpneumonia 
ARI hospitalizations was 24.6 per 1,000 in 2005 and 21.9 
per 1,000 in 2006. The rate in 2006 represented a signifi-
cant decline from the rate of 28.1 during the baseline period 
(RR = 0.8). For 2006, this rate reduction represented an 
estimated 51,500 fewer nonpneumonia ARI hospitalizations 
among children aged <2 years during 2006 compared with the 
average annual number of hospitalizations during 1997–1999. 
Among children aged 2–4 years, the rate of nonpneumonia 
ARI hospitalizations was 6.5 per 1,000 in 2005 and 5.6 per 
1,000 in 2006. The 2006 rate was not significantly different 
compared with the baseline period (RR = 1.0).
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Annual rates for all nonbirth-related hospitalizations among 
children aged <2 years were 120 per 1,000 children in 2005 and 
100 per 1,000 children in 2006, compared with 117 per 1,000 
children during the baseline period. The proportion of total 
annual nonbirth-related hospitalizations coded as pneumonia 
was 8% in 2006, compared with 11% during the baseline 
period (p<0.001). The proportion of such hospitalizations 
coded as nonpneumonia ARI was 22% in 2006, compared 
with 24% during the baseline period (p=0.005).
Reported by: CG Grijalva, MD, MR Griffin, MD, Vanderbilt Univ, 
Nashville, Tennessee. JP Nuorti, MD, Respiratory Diseases Br, National 
Center for Immunization and Respiratory Diseases; ND Walter, MD, 
EIS Officer, CDC.
Editorial Note: The results of this analysis cannot, by them-
selves, establish a causal relationship between the advent of 
PCV7 and trends in childhood pneumonia hospitalizations. 
However, the updated analysis of national hospital discharge 
data suggests that reductions in all-cause pneumonia hospital-
izations among U.S. children aged <2 years after routine PCV7 
use have been sustained and that the benefits of PCV7 might 
extend beyond the documented changes in IPD (3) to hospi-
talizations for pneumonia. Moreover, rates of nonpneumonia 
ARI also declined after introduction of PCV7, indicating that 
the decreases in pneumonia hospitalizations likely were not 
the result of a shift in coding of respiratory hospitalizations to 
nonpneumonia ARI codes. In addition, the analysis suggests 
that the declines were unlikely to result from a reduction in 
total hospitalization rates. The transient increase in all-cause 
pneumonia rates from 2004 to 2005 might reflect increased 
circulation of respiratory viruses or other seasonal variation.
Although many nonpneumonia ARI diagnoses traditionally 
have not been considered manifestations of S. pneumoniae 
infection, recent data indicate that the pneumococcus might 
contribute to a wider range of childhood respiratory illness than 
previously thought. A randomized clinical trial performed in 
child care centers in Israel suggested that immunization with 
a 9-valent pneumococcal conjugate vaccine reduced reported 
episodes of upper respiratory infections, lower respiratory infec-
tions, and otitis media by 15%, 16%, and 17%, respectively 
(7). Furthermore, in a trial of 9-valent pneumococcal conjugate 
vaccine among South African children, vaccinated children had 
45% fewer influenza A–associated pneumonia episodes than 
unvaccinated children, suggesting that S. pneumoniae might 
be a copathogen in illnesses diagnosed as influenza (8).
Although rates of IPD have decreased substantially among 
children aged 2–4 years after PCV7 introduction (3), a 
reduction in all-cause pneumonia hospitalizations was not 
observed in this age group. The reasons for this are unknown 
but might be associated with lower overall rates of pneumo-
coccal infection in this age group. In addition, other etiologic 
agents are becoming more common causes of pneumonia in 
children aged >2 years (1).
FIGURE. Annual all-cause pneumonia hospitalizations rates* 
among children aged <2 years and 2–4 years — Nationwide 





















* Per 1,000 population.
† 95% confidence interval.
§ 7-valent pneumococcal conjugate vaccine licensed in February 2000.
TABLE. Hospitalization rates for all-cause pneumonia and nonpneumonia acute respiratory illness among children aged <2 years 
and 2–4 years before and after pneumococcal conjugate vaccine introduction — Nationwide Inpatient Sample, United States, 
1997–1999, 2005, and 2006
Syndrome/Age group
1997–1999
Rate ratio 2006 




Rate (95% CI) Rate (95% CI) Rate ratio (95% CI)
All-cause pneumonia
<2 yrs 12.5 (11.8–13.3) 9.1 (8.1–10.3) 8.1 (7.5–8.9) 0.7 (0.6–0.7)
2–4 yrs 4.1 (3.8–4.3) 4.8 (4.3–5.3) 3.9 (3.5–4.3) 1.0 (0.9–1.1)
Nonpneumonia ARI§
<2 yrs 28.1 (26.4–30.0) 24.6 (21.4–28.3) 21.9 (19.7–24.3) 0.8 (0.7–0.9)
2–4 yrs 5.8 (5.6–6.1) 6.5 (6.1–7.0) 5.6 (5.2–6.0) 1.0 (0.9–1.0)
 * Per 1,000 population.
 † Confidence interval.
 § Acute respiratory illness.
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The findings in this report are subject to at least three limita-
tions. First, identification of hospitalizations for pneumonia 
and nonpneumonia ARI was based on ICD-9-CM codes and 
might be subject to misclassification, despite internal quality 
control and validation for consistency within the Nationwide 
Inpatient Sample. Second, establishing the etiology of pneu-
monia is difficult. Nationwide Inpatient Sample data are 
deidentified before public release and chart reviews cannot be 
performed to confirm recorded diagnoses. Because most pneu-
mococcal pneumonias are classified as pneumonias without 
further characterization, this report provides an estimate of 
the effect of PCV7 on all-cause pneumonia without regard to 
pneumococcal serotypes. Furthermore, serotyping is not part of 
routine diagnostic work-ups, and this information would not 
be recorded in medical charts. However, the decrease in non-
pneumonia ARI hospitalizations among children aged <2 years 
suggests that the decreases in pneumonia hospitalizations 
were unlikely to result from a shift in coding of pneumonia 
to nonpneumonia ARI codes. Finally, factors other than shifts 
in coding could affect hospitalization rates. Reduced clinician 
concerns for severe pneumococcal disease among immunized 
children, for example, might lead to outpatient treatment 
rather than hospitalization. However, other data indicate that 
ambulatory-care visits for pneumonia among children aged 
<2 years also have decreased since introduction of PCV7 (5). 
In addition, the proportion of all hospitalizations that were 
attributable to pneumonia or nonpneumonia ARI decreased 
significantly, suggesting that the declines were unlikely to result 
from a secular reduction in overall hospitalization rate.
Despite the substantial morbidity associated with childhood 
pneumonia, no pneumonia-specific prospective population-
based surveillance system exists for monitoring trends in the 
incidence of pneumonia hospitalizations or pneumonia-related 
ambulatory-care visits in the United States. Monitoring child-
hood pneumonia is important for the evaluation of effects of 
current and future pneumococcal immunization programs. 
Increases in pneumococcal disease caused by serotypes not 
included in PCV7 could result in some increase in pneumonia, 
even though observed increases in non-PCV7 serotype IPD 
have been modest thus far (9). In addition, extended-valency 
pneumococcal conjugate vaccines are expected to be licensed 
by late 2009 to early 2010 and might further reduce pneumo-
nia rates. Finally, vaccination of children against influenza, as 
recommended by the Advisory Committee on Immunization 
Practices, is increasing and also might reduce pneumonia 
hospitalization rates (10).
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Possible Congenital Infection 
with La Crosse Encephalitis Virus — 
West Virginia, 2006–2007
La Crosse encephalitis virus (LACV) is a mosquitoborne 
bunyavirus of the California encephalitis serogroup (1). During 
2003–2007, West Virginia had the greatest number of cases 
(95) and highest incidence of LACV disease (5.1 cases per 
100,000 population) of any state.* The majority of persons 
infected with LACV either have no symptoms or a mild 
febrile illness; a limited number experience encephalitis (2). 
Although only 1%–4% of those infected with LACV develop 
any symptoms, children aged <16 years are at highest risk 
for severe neurologic disease and possible long-term sequelae 
(2,3). The effects of LACV infection during pregnancy and 
the potential for intrauterine transmission and adverse birth or 
developmental outcomes are unknown. This report describes 
the first known case of LACV infection in a pregnant woman, 
with evidence of possible congenital infection with LACV in 
her infant, based on the presence of immunoglobulin M (IgM) 
* Confirmed and probable California serogroup viral (mainly La Crosse) 
encephalitis cases, human, United States, 1964–2007, by state. Available at 
http://www.cdc.gov/ncidod/dvbid/arbor/pdf/cal_lac.pdf.
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antibodies in umbilical cord serum at delivery. The infant was 
born healthy with normal neurologic and cognitive functions 
and no LACV symptoms. Further investigation is needed to 
confirm the potential for intrauterine LACV transmission 
and to identify immediate and long-term health risks posed 
to infants. Because of the potential for congenital infection, 
pregnant women in areas where LACV is endemic should be 
advised to avoid mosquitoes; health-care providers should 
monitor for LACV infection and sequelae among infants born 
to women infected with LACV during pregnancy.
In August 2006, a previously healthy woman aged 43 years 
in week 21 of her pregnancy was admitted to a West Virginia 
hospital after experiencing severe headaches, photophobia, stiff 
neck, fever, weakness, confusion, and a red papular rash. The 
patient had reported a 3-month history of severe headaches, 
which were diagnosed initially as migraines and treated with 
morphine for pain. Two previous pregnancies had proceeded 
without complication, and each resulted in delivery of a healthy 
infant. The patient’s medical history included anxiety, depres-
sion, and hypothyroidism, for which she received ongoing 
thyroid hormone replacement therapy.
After hospital admission, analysis of cerebrospinal fluid 
revealed an elevated white blood cell count (556 cells/mm3 
[94% lymphocytes, 5% monocytes, and 1% polymor-
phonuclear neutrophilic leukocytes]), elevated protein 
(66 mg/dL), and normal glucose (55 mg/dL). A diagnostic 
panel for viral encephalitis was performed, and the patient’s 
serum was determined positive for the presence of LACV-
specific IgM and immunoglobulin G (IgG) antibodies by 
immunofluorescence assay and for IgM by capture enzyme-
linked immunosorbent assay (ELISA) (Table). The patient’s 
serum was negative for IgM and IgG antibodies to the other 
three diseases in the diagnostic panel: eastern equine encepha-
litis, western equine encephalitis, and St. Louis encephalitis. A 
diagnosis of La Crosse encephalitis was made, and supportive 
therapy was initiated. During hospitalization, the patient 
experienced a low-grade fever and exhibited panleukocytosis 
(absolute neutrophil count: 12,800/µL), which persisted after 
discharge despite resolution of clinical signs.
After reporting the case to the West Virginia Department of 
Health and Human Resources, active follow-up of the patient 
and her fetus was initiated in collaboration with the patient’s 
primary-care providers and CDC. With her consent, the 
patient’s medical and prenatal histories were reviewed. Because 
guidelines for evaluating pregnant women infected with LACV 
do not exist, interim guidelines for West Nile virus were used 
to direct maternal and infant follow-up (4). Specifically, col-
lection of blood and tissue products at time of delivery was 
arranged with the patient’s obstetrician. Umbilical cord serum 
and maternal serum were tested for LACV-specific antibodies 
by ELISA and serum-dilution plaque-reduction neutralization 
test (PRNT). Sera also were tested for neutralizing antibodies 
to the closely related Jamestown Canyon virus by PRNT to 
rule out potential cross-reactivity. Umbilical cord and placental 
tissue were tested for LACV RNA by reverse transcription–
polymerase chain reaction (RT-PCR). Data were collected 
regarding the infant’s health at delivery and through routine 
well-child visits during the first 6 months of life.
The patient had a normal, spontaneous, vaginal delivery of 
a healthy girl at approximately 40 weeks gestation. The child 
TABLE. Summary of laboratory test results during investigation and follow-up of possible congenital infection with La Crosse 
encephalitis virus (LACV) — West Virginia, 2006–2007
Collection date Specimen Test Result
August 20, 2006 Maternal serum LACV IgM*capture ELISA† Positive
Maternal serum LACV IgM IFA§ Positive
Maternal serum LACV IgG¶ IFA Positive
Maternal serum LACV neutralizing antibodies PRNT** Positive
Maternal serum JCV†† neutralizing antibodies PRNT Negative
January 5, 2007 Placental tissue LACV RNA RT-PCR§§ Negative
Umbilical cord tissue LACV RNA RT-PCR Negative
Umbilical cord serum LACV IgM capture ELISA Positive
Umbilical cord serum LACV IgG capture ELISA Equivocal
Umbilical cord serum LACV neutralizing antibodies PRNT Positive
Umbilical cord serum JCV neutralizing antibodies PRNT Negative
March 23, 2007 Maternal serum LACV IgM capture ELISA Negative
Maternal serum LACV IgG capture ELISA Positive
 * Immunoglobulin M.
 † Enzyme-linked immunosorbent assay.
 § Immunofluorescence assay.
 ¶ Immunoglobulin G. 
 ** Plaque-reduction neutralization test.
 †† Jamestown Canyon virus.
 §§ Reverse transcription–polymerase chain reaction.
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had normal birth weight (2,970 g), length (52 cm), and head 
circumference (33 cm). Apgar scores at 1 minute and 5 minutes 
postpartum were within normal limits (8 and 9, respectively). 
LACV-specific IgM antibodies were detected in umbilical cord 
serum, although no evidence of LACV RNA was detected in 
umbilical cord tissue or placental tissue by RT-PCR (Table).
The mother declined collection of additional specimens of 
infant serum for confirmation of congenital LACV infection. 
Maternal serum collected at 11 weeks postpartum was positive 
for LACV IgG antibodies but negative for IgM. Except for 
intermittent nasal congestion associated with upper respiratory 
infections, the infant remained healthy and exhibited appropri-
ate growth and development through the first 6 months of life. 
No neurologic abnormalities or decreased cognitive functions 
were observed.
Reported by: A Hinckley, PhD, Div of Vector-Borne Infectious Diseases, 
National Center for Zoonotic, Vector-Borne, and Enteric Diseases; 
A Hall, DVM, EIS Officer, CDC.
Editorial Note: This report summarizes the first case of 
symptomatic LACV infection identified during pregnancy. 
Congenital LACV infection of the fetus was suggested through 
identification of IgM antibodies in umbilical cord serum, 
although the newborn was asymptomatic and development 
was normal. Although unlikely to cross the placental barrier, 
LACV IgM antibodies detected in cord serum might have 
been attributable to transplacental leakage induced by uterine 
contractions that disrupt placental barriers during labor, which 
has been documented for anti-Toxoplasma IgM antibodies (5). 
Because specificity of standard laboratory techniques used to 
detect LACV IgM antibodies in cord serum or newborn serum 
is unknown, a follow-up evaluation of infant serum is neces-
sary to confirm congenital infection. However, in this case, 
the mother declined collection of any additional specimens 
from her infant.
Certain infectious diseases have more severe clinical presenta-
tions in pregnant women (6). Symptomatic LACV infection is 
rare among adults; therefore, effects of pregnancy on the risk for 
or severity of illness are unknown. Because LACV-specific IgM 
can be present for as long as 9 months after infection (1), LACV 
might not have been responsible for the symptoms reported 
during this woman’s pregnancy. However, the woman resided 
in an area where LACV is known to be endemic; during 2006, 
16 (24%) of 67 LACV cases in the United States reported to 
CDC occurred in West Virginia, including three other cases 
from the same county as this patient.† Although antimicrobial 
treatment of pregnant women often is controversial because 
of limited information regarding efficacy and risk to the 
developing infant (7), certain in vitro evidence indicates that 
the antiviral agent ribavirin might be useful for treating LACV 
infection in nonpregnant patients (2). However, supportive 
treatment continues as the standard of care for managing all 
LACV patients (2).
Congenital infection with other arboviral diseases has been 
reviewed and documented previously (8). Although no human 
congenital infection with a bunyavirus of the California 
serogroup has been reported, congenital infection with other 
bunyaviruses of the Bunyamwera serogroup has been associ-
ated with macrocephaly. In addition, animal studies have 
determined that infection with LACV during pregnancy can 
cause teratogenic effects in domestic rabbits, Mongolian gerbils, 
and sheep (9,10).
Pregnant women in areas where LACV is endemic should 
take precautions to reduce risk for infection by avoiding mos-
quitoes, wearing protective clothing, and applying a mosquito 
repellent to skin and clothing. Additionally, health-care pro-
viders serving areas where LACV is endemic should consider 
LACV in the differential diagnosis of viral encephalitis. As 
a nationally notifiable disease, all probable and confirmed 
cases of LACV should be reported to the appropriate state 
and local public health authorities. When LACV infection is 
suspected in a pregnant woman or infant, appropriate serologic 
and virologic testing by a public health reference laboratory 
is recommended. Testing breast milk for the presence of 
LACV also might be reasonable to evaluate the potential for 
maternal-infant transmission and to determine the suitability 
for continued breastfeeding. Additional investigations are 
needed to confirm the potential for congenital infection with 
LACV and to identify immediate and long-term health risks 
LACV poses to infants.
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Updated Guidelines for the Use 
of Nucleic Acid Amplification Tests 
in the Diagnosis of Tuberculosis
Guidelines for the use of nucleic acid amplification (NAA) 
tests for the diagnosis of tuberculosis (TB) were published in 
1996 (1) and updated in 2000 (2). Since then, NAA testing 
has become a routine procedure in many settings because 
NAA tests can reliably detect Mycobacterium tuberculosis 
bacteria in specimens 1 or more weeks earlier than culture 
(3). Earlier laboratory confirmation of TB can lead to earlier 
treatment initiation, improved patient outcomes, increased 
opportunities to interrupt transmission, and more effective 
public health interventions (4,5). Because of the increasing 
use of NAA tests and the potential impact on patient care 
and public health, in June 2008, CDC and the Association of 
Public Health Laboratories (APHL) convened a panel of clini-
cians, laboratorians, and TB control officials to assess existing 
guidelines (1,2) and make recommendations for using NAA 
tests for laboratory confirmation of TB. On the basis of the 
panel’s report and consultations with the Advisory Council 
for the Elimination of TB (ACET),* CDC recommends that 
NAA testing be performed on at least one respiratory specimen 
from each patient with signs and symptoms of pulmonary TB 
for whom a diagnosis of TB is being considered but has not 
yet been established, and for whom the test result would alter 
case management or TB control activities, such as contact 
investigations. These guidelines update the previously pub-
lished guidelines (1,2).
Background
Conventional tests for laboratory confirmation of TB include 
acid-fast bacilli (AFB) smear microscopy, which can produce 
results in 24 hours, and culture, which requires 2–6 weeks to 
produce results (5,6). Although rapid and inexpensive, AFB 
smear microscopy is limited by its poor sensitivity (45%–80% 
with culture-confirmed pulmonary TB cases) and its poor 
positive predictive value (50%–80%) for TB in settings in 
which nontuberculous mycobacteria are commonly isolated 
(3,6,7).
NAA tests can provide results within 24–48 hours. The 
Amplified Mycobacterium tuberculosis Direct Test (MTD, 
Gen-Probe, San Diego, California) was approved by the Food 
and Drug Administration (FDA) in 1995 for use with AFB 
smear-positive respiratory specimens, and in a supplement 
application, an enhanced MTD test was approved in 1999 
for use with AFB smear-negative respiratory specimens from 
patients suspected to have TB. In addition, the Amplicor 
Mycobacterium tuberculosis Test (Amplicor, Roche Diagnostics, 
Basel, Switzerland) was approved by FDA in 1996 for use 
with AFB smear-positive respiratory specimens from patients 
suspected to have TB. NAA tests for TB that have not been 
FDA-approved also have been used clinically (e.g., NAA tests 
based on analyte specific reagents, often called “home-brew” 
or “in-house” tests) (8,9).
Compared with AFB smear microscopy, the added value 
of NAA testing lies in its 1) greater positive predictive value 
(>95%) with AFB smear-positive specimens in settings in 
which nontuberculous mycobacteria are common and 2) ability 
to confirm rapidly the presence of M. tuberculosis in 50%–80% 
of AFB smear-negative, culture-positive specimens (3,7–9). 
Compared with culture, NAA tests can detect the presence of 
M. tuberculosis bacteria in a specimen weeks earlier than culture 
for 80%–90% of patients suspected to have pulmonary TB 
whose TB is ultimately confirmed by culture (3,8,9). These 
advantages can impact patient care and TB control efforts, such 
as by avoiding unnecessary contact investigations or respiratory 
isolation for patients whose AFB smear-positive specimens do 
not contain M. tuberculosis.
Despite being commercially available for more than a decade 
(1), NAA tests for TB have not been widely used in the United 
States largely because of 1) an uncertainty as to whether 
NAA test results influence case-management decisions or TB 
control activities; 2) a lack of information on the overall cost-
effectiveness of NAA testing for TB; and 3) a lack of demand 
from clinicians and public health authorities. However, recent * Additional information regarding ACET is available at http://www.cdc.gov/maso/facm/facmacet.htm.
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studies showed that 1) clinicians already rely on the NAA test 
result as the deciding factor for the initiation of therapy for 
20%–50% of TB cases in settings where NAA testing is a rou-
tine practice (4,7) and 2) overall cost savings can be achieved by 
using NAA test results for prioritizing contact investigations, 
making decisions regarding respiratory isolation, or reducing 
nonindicated TB treatment (4,7).
In response to the increasing demand for NAA testing for 
TB and recognition of the importance of prompt laboratory 
results in TB diagnosis and control, ACET requested that 
APHL and CDC convene a panel to evaluate the available 
information (e.g., current practices, existing guidelines, and 
publications) and to propose new guidelines for the use of 
NAA tests for TB diagnosis. The panel met in June 2008 and 
included TB clinicians; TB control officials; laboratory direc-
tors or supervisors from small, medium, and large public health 
laboratories, hospital laboratories, and commercial laboratories; 
and representatives from the TB Regional Training and Medical 
Consultation Centers, ACET, APHL, and CDC. In brief, the 
panel recommended† that NAA testing become a standard 
practice in the United States to aid in the initial diagnosis of 
patients suspected to have TB, rather than just being a reason-
able approach, as suggested in previously published guidelines 
(1,2). On the basis of the panel’s report and consultations with 
ACET, CDC developed revised guidelines.
Updated Recommendation
NAA testing should be performed on at least one respira-
tory specimen from each patient with signs and symptoms of 
pulmonary TB for whom a diagnosis of TB is being considered 
but has not yet been established, and for whom the test result 
would alter case management or TB control activities. The 
following testing and interpretation algorithm is proposed.
Revised Testing and Interpretation 
Algorithm
1. Routinely collect respiratory specimens (e.g., sputum), 
process (liquefy, decontaminate, and concentrate), and 
test by AFB smear microscopy and culture as previously 
recommended (6). Specimen collection and microbiologic 
testing should not be delayed to await NAA test results.
2. At least one specimen, preferably the first diagnostic speci-
men, from each patient to be tested by NAA should be 
processed, suspended in a sufficient volume of buffer to 
ensure adequate sample volume for all planned tests (e.g., 
microscopy, culture, and NAA), and tested using an NAA 
test for TB. NAA testing should be performed in accordance 
with the manufacturer’s instructions or a validated standard 
operating procedure.
3. Interpret NAA test results in correlation with the AFB smear 
results.
a. If the NAA result is positive and the AFB smear result is 
positive, presume the patient has TB and begin anti-TB 
treatment while awaiting culture results. The positive 
predictive value of FDA-approved NAA tests for TB is 
>95% in AFB smear-positive cases (8).
b. If the NAA result is positive and the AFB smear result is 
negative, use clinical judgment whether to begin anti-TB 
treatment while awaiting culture results and determine 
if additional diagnostic testing is needed. Consider 
testing an additional specimen using NAA to confirm 
the NAA result. A patient can be presumed to have TB, 
pending culture results, if two or more specimens are 
NAA positive.
c. If the NAA result is negative and the AFB smear result 
is positive, a test for inhibitors should be performed 
and an additional specimen should be tested with NAA. 
Sputum specimens (3%–7%) might contain inhibitors 
that prevent or reduce amplification and cause false-
negative NAA results (8,9).
i. If inhibitors are detected, the NAA test is of no diag-
nostic help for this specimen. Use clinical judgment 
to determine whether to begin anti-TB treatment 
while awaiting results of culture and additional 
diagnostic testing.
ii. If inhibitors are not detected, use clinical judgment 
to determine whether to begin anti-TB treatment 
while awaiting culture results and determine if addi-
tional diagnostic testing is needed. A patient can be 
presumed to have an infection with nontuberculous 
mycobacteria if a second specimen is smear positive 
and NAA negative and has no inhibitors detected.
d. If the NAA result is negative and the AFB smear result is 
negative, use clinical judgment to determine whether to 
begin anti-TB treatment while awaiting results of culture 
and additional diagnostic tests. Currently available NAA 
tests are not sufficiently sensitive (detecting 50%–80% 
of AFB smear-negative, culture-positive pulmonary TB 
cases) to exclude the diagnosis of TB in AFB smear-
negative patients suspected to have TB (8,9).
Cautions
Culture remains the gold standard for laboratory con-
firmation of TB and is required for isolating bacteria for 
drug-susceptibility testing and genotyping. In accordance 
† The full report and recommendations of the panel (released in December 2008) 
are available at http://www.cdc.gov/tb/amplification_tests/amplification_tests.
pdf.
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with current recommendations (6), sufficient numbers and 
portions of specimens should always be reserved for culturing. 
Nonetheless, NAA testing should become standard practice for 
patients suspected to have TB, and all clinicians and public 
health TB programs should have access to NAA testing for TB 
to shorten the time needed to diagnose TB from 1–2 weeks 
to 1–2 days (3). More rapid laboratory results should lead to 
earlier treatment initiation, improved patient outcomes, and 
increased opportunities to interrupt transmission (4,5). Rapid 
laboratory confirmation of TB also can help reduce inap-
propriate use of fluoroquinolones as empiric monotherapy of 
pneumonias, a practice which is suspected to lead to develop-
ment of fluoroquinolone-resistant M. tuberculosis and delays 
in initiating appropriate anti-TB therapy (10).
To maximize benefits of NAA testing, the interval from 
specimen collection to communication of the laboratory report 
to the treating clinician should be as brief as possible. NAA 
test results should be available within 48 hours of specimen 
collection. Laboratorians should treat an initial positive NAA 
test result as a critical test value, immediately report the result 
to the clinician and public health authorities, and be available 
for consultation regarding test interpretation and the possible 
need for additional testing.
Although NAA testing is recommended to aid in the ini-
tial diagnosis of persons suspected to have TB, the currently 
available NAA tests should not be ordered routinely when the 
clinical suspicion of TB is low, because the positive predictive 
value of the NAA test is <50% for such cases (8). Clinicians, 
laboratorians, and TB control officials should be aware of the 
appropriate uses of NAA tests.
Clinicians should interpret all laboratory results on the 
basis of the clinical situation. A single negative NAA test 
result should not be used as a definitive result to exclude TB, 
especially when the clinical suspicion of TB is moderate to 
high. Rather, the negative NAA test result should be used as 
additional information in making clinical decisions, to expedite 
testing for an alternative diagnosis, or to prevent unnecessary 
TB treatment. Consultation with a TB expert should be con-
sidered if the clinician is not experienced in the interpretation 
of NAA tests or the diagnosis and treatment of TB.
Although FDA-approved NAA tests for TB are eligible for 
Medicare or Medicaid reimbursement, the costs of adding 
NAA testing to the routine testing of respiratory specimens 
from patients suspected to have TB might be considerable (e.g., 
operating costs exceed $100 per MTD test) (8). However, NAA 
testing has the potential to provide overall cost savings to the 
treatment center and TB control program through reduced 
costs for isolation, reduced costs of contact investigations 
of persons who do not have TB, and increased opportuni-
ties to prevent transmission. Within the parameters of these 
guidelines, each TB control or treatment program should evalu-
ate the overall costs and benefits of NAA testing in deciding 
the value and optimal use of the test in their setting.
Because the testing algorithm includes NAA testing of 
AFB smear-negative specimens, laboratories must use an 
FDA-approved test for such specimens or a test produced 
and validated in accordance with applicable FDA and Clinical 
Laboratory Improvement Amendments (CLIA) regulations.§ 
However, the performance of in-house tests or FDA-approved 
tests used for nonapproved indications (off-label use) is vari-
able (8,9), and insufficient information is available to provide 
recommendations on the use of such tests for the diagnosis of 
TB. Their use should be guided by the clinical context, and the 
results of such tests should be interpreted on the basis of per-
formance in the local laboratory and in validation studies.
For procedural and economic reasons, NAA testing might 
be impractical in laboratories with a small volume of testing. 
Referral of samples for NAA testing to high-volume laborato-
ries might be preferable to improve cost-efficiency, proficiency, 
and turnaround times. The New York and Florida Fast Track 
Programs are successful NAA testing services that could serve 
as models for a regional service (5).
Information is limited regarding NAA test performance for 
nonrespiratory specimens or specimens from patients under 
treatment (8). NAA results often remain positive after culture 
results become negative during therapy. Further research is 
needed before specific recommendations can be made on the 
use of NAA testing in the diagnosis of extrapulmonary TB and 
TB in children who cannot produce sputum; however, evidence 
exists for the utility of such testing in individual cases (8).
These guidelines do not address the use of molecular tests for 
detecting drug resistance, which is an urgent public health and 
diagnostic need. No molecular drug-susceptibility tests (DSTs) 
have been approved by FDA for use in the United States, 
although well-characterized molecular DSTs are commercially 
available in Europe and elsewhere.¶ Nonetheless, a proposed 
revision of the Diagnostic Standards and Classification of 
Tuberculosis in Adults and Children (6) is likely to support 
the use of molecular DSTs for AFB smear-positive sputum 
sediments from TB patients who are suspected to have drug-
resistant disease or who are from a region or population with 
a high prevalence of drug resistance.
Reported by: Div of Tuberculosis Elimination, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
§ Information on ASR regulations (21 CFR 809.10(e), 809.30, and 864.4020) is 
available at http://www.fda.gov/cdrh/oivd/guidance/1590.html. Information on 
the Clinical Laboratory Improvement Amendments (42 CFR 493) is available 
at http://wwwn.cdc.gov/clia/regs/toc.aspx.
¶ Additional information available at http://www.who.int/tb/features_archive/
expert_group_report_june08.pdf.
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Erratum: Vol. 57, No. 40
In the report, “Vaccination Coverage Among Adolescents 
Aged 13–17 Years — United States, 2007,” on page 1100, in 
the second footnote, an error occurred. The first sentence of 
the footnote should read as follows:
“† NIS–Teen 2007 was conducted during the fourth quarter 
2007 only; eligible participants were born during October 5, 
1989–February 14, 1995.”
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, 









Total cases reported 
for previous years States reporting cases
during current week (No.)2008 2007 2006 2005 2004
Anthrax — — — — 1 1 — —
Botulism:
 foodborne — — 0 13 32 20 19 16
 infant — — 2 98 85 97 85 87
 other (wound and unspecified) — — 1 24 27 48 31 30
Brucellosis — — 3 84 131 121 120 114
Chancroid — — 0 31 23 33 17 30
Cholera — — 0 2 7 9 8 6
Cyclosporiasis§ 1 1 2 127 93 137 543 160 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases§,¶:
 California serogroup — — — 40 55 67 80 112
 eastern equine — — — 2 4 8 21 6
 Powassan — — — 1 7 1 1 1
 St. Louis — — 0 10 9 10 13 12
 western equine — — — — — — — —
Ehrlichiosis/Anaplasmosis§,**:
 Ehrlichia chaffeensis 3 3 16 855 828 578 506 338 ME (1), NC (1), FL (1)
 Ehrlichia ewingii — — — 9 — — — —
 Anaplasma phagocytophilum — — 25 494 834 646 786 537
 undetermined — — 2 69 337 231 112 59
Haemophilus influenzae,†† 
invasive disease (age <5 yrs):
 serotype b — — 1 27 22 29 9 19
 nonserotype b 1 1 5 169 199 175 135 135 NC (1)
 unknown serotype 2 2 5 191 180 179 217 177 NY (1), FL (1)
Hansen disease§ — — 2 72 101 66 87 105
Hantavirus pulmonary syndrome§ — — 1 16 32 40 26 24
Hemolytic uremic syndrome, postdiarrheal§ 1 1 6 237 292 288 221 200 CA (1)
Hepatitis C viral, acute 90 90 21 840 845 766 652 720 OH (3), IN (1), KY (2), TN (1), TX (1), AZ (81), CA (1)
HIV infection, pediatric (age <13 years)§§ — — 2 — — — 380 436
Influenza-associated pediatric mortality§,¶¶ — — 1 90 77 43 45 —
Listeriosis 7 7 17 670 808 884 896 753 NY (1), OH (1), GA (1), TN (1), CA (3)
Measles*** — — 1 134 43 55 66 37
Meningococcal disease, invasive†††:
 A, C, Y, and W-135 1 1 7 302 325 318 297 — NV (1)
 serogroup B — — 5 154 167 193 156 —
 other serogroup — — 1 30 35 32 27 —
 unknown serogroup 6 6 19 593 550 651 765 — OH (2), VA (1), NC (1), FL (1), CA (1)
Mumps 2 2 15 391 800 6,584 314 258 TN (1), HI (1)
Novel influenza A virus infections — — — 1 4 N N N
Plague — — 0 1 7 17 8 3
Poliomyelitis, paralytic — — — — — — 1 —
Polio virus infection, nonparalytic§ — — — — — N N N
Psittacosis§ 1 1 0 12 12 21 16 12 PA (1)
Q fever total§,§§§: — — 2 116 171 169 136 70
 acute — — 0 103 — — — —
 chronic — — — 13 — — — —
Rabies, human — — 0 1 1 3 2 7
Rubella¶¶¶ 2 2 0 17 12 11 11 10 AZ (1), UT (1)
Rubella, congenital syndrome — — — — — 1 1 —
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — — 4 131 132 125 129 132
Syphilis, congenital (age <1 yr) — — 7 229 430 349 329 353
Tetanus 1 1 1 16 28 41 27 34 UT (1)
Toxic-shock syndrome (staphylococcal)§ 1 1 3 69 92 101 90 95 TN (1)
Trichinellosis — — 0 37 5 15 16 5
Tularemia — — 2 106 137 95 154 134
Typhoid fever 1 1 9 396 434 353 324 322 CA (1)
Vancomycin-intermediate Staphylococcus aureus§ — — 0 33 37 6 2 —
Vancomycin-resistant Staphylococcus aureus§ — — 0 — 2 1 3 1
Vibriosis (noncholera Vibrio species infections)§ 3 3 4 451 549 N N N NC (2), FL (1)
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — 
United States, week ending January 10, 2009 (1st week)*
—: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts. 
 * Incidence data for reporting year 2008 and 2009 are provisional, whereas data for 2004, 2005, 2006, and 2007 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 
5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 § Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and 
influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-
Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, 
human monocytic (analogous to E. chaffeensis); Ehrlichiosis, human granulocytic (analogous to Anaplasma phagocytophilum), and Ehrlichiosis, unspecified, or other agent 
(which included cases unable to be clearly placed in other categories, as well as possible cases of E. ewingii). 
 †† Data for H. influenzae (all ages, all serotypes) are available in Table II.
 §§ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting 
influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data 
management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 ¶¶ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. No confirmed influenza-associated pediatric deaths have 
been reported for the current 2008-09 season.
 *** No measles cases were reported for the current week.
 ††† Data for meningococcal disease (all serogroups) are available in Table II.
 §§§ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not 
differentiated with respect to acute and chronic Q fever cases.
 ¶¶¶ The two rubella cases reported for the current week were unknown.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. 
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods 
for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of 
these 4-week totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 
4-week totals January 10, 2009, with historical data
Notifiable Disease Data Team and 122 Cities Mortality Data Team
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52 week Cum  
2009
Cum  
2008Med Max Med Max Med Max
United States 8,115 21,476 25,221 8,115 13,869 103 122 322 103 308 20 100 431 20 85
New England 369 707 1,048 369 441 — 0 1 — — — 5 20 — 40
Connecticut — 210 473 — 78 N 0 0 N N — 0 0 — 38
Maine§ 56 51 72 56 43 N 0 0 N N — 0 6 — —
Massachusetts 225 329 623 225 244 N 0 0 N N — 1 9 — 1
New Hampshire 32 42 64 32 17 — 0 1 — — — 1 4 — 1
Rhode Island§ 29 55 208 29 53 — 0 0 — — — 0 3 — —
Vermont§ 27 15 52 27 6 N 0 0 N N — 1 7 — —
Mid. Atlantic 315 2,763 5,097 315 1,593 — 0 0 — — 1 12 34 1 7
New Jersey — 442 576 — 298 N 0 0 N N — 0 2 — 1
New York (Upstate) 145 532 1,355 145 5 N 0 0 N N 1 4 17 1 —
New York City — 1,011 3,412 — 578 N 0 0 N N — 2 6 — 2
Pennsylvania 170 814 1,088 170 712 N 0 0 N N — 5 15 — 4
E.N. Central 975 3,528 4,285 975 3,008 — 1 3 — 1 4 25 126 4 18
Illinois 37 1,084 1,394 37 749 N 0 0 N N — 2 13 — 2
Indiana 313 377 713 313 463 N 0 0 N N — 3 12 — —
Michigan 585 841 1,226 585 494 — 0 3 — — — 5 13 — 6
Ohio — 805 1,261 — 930 — 0 2 — 1 4 6 59 4 7
Wisconsin 40 320 615 40 372 N 0 0 N N — 9 46 — 3
W.N. Central 165 1,268 1,696 165 806 — 0 2 — — 3 16 68 3 3
Iowa — 174 240 — 71 N 0 0 N N — 4 30 — 3
Kansas 107 179 529 107 110 N 0 0 N N — 1 8 — —
Minnesota — 266 373 — 195 — 0 0 — — — 4 15 — —
Missouri — 490 566 — 272 — 0 2 — — 2 3 13 2 —
Nebraska§ — 80 244 — 70 N 0 0 N N 1 2 8 1 —
North Dakota 3 34 58 3 52 N 0 0 N N — 0 2 — —
South Dakota 55 55 85 55 36 N 0 0 N N — 1 9 — —
S. Atlantic 2,919 3,645 6,324 2,919 1,889 — 0 1 — — 11 17 46 11 9
Delaware 48 69 150 48 36 — 0 1 — — — 0 2 — —
District of Columbia 99 127 207 99 81 — 0 0 — — — 0 2 — —
Florida 1,135 1,368 1,571 1,135 824 N 0 0 N N 7 7 35 7 5
Georgia 4 458 1,307 4 159 N 0 0 N N 4 4 13 4 1
Maryland§ 367 439 692 367 179 — 0 1 — — — 1 4 — —
North Carolina — 0 1,208 — — N 0 0 N N — 0 16 — —
South Carolina§ 840 478 3,043 840 260 N 0 0 N N — 1 4 — 1
Virginia§ 420 621 1,059 420 314 N 0 0 N N — 1 4 — —
West Virginia 6 60 102 6 36 N 0 0 N N — 0 3 — 2
E.S. Central 954 1,567 2,302 954 1,026 — 0 0 — — — 3 9 — 1
Alabama§ — 456 561 — 363 N 0 0 N N — 1 6 — 1
Kentucky 374 240 373 374 155 N 0 0 N N — 0 4 — —
Mississippi — 390 1,048 — 187 N 0 0 N N — 0 2 — —
Tennessee§ 580 534 792 580 321 N 0 0 N N — 1 6 — —
W.S. Central 329 2,781 3,530 329 1,901 — 0 1 — — — 5 155 — —
Arkansas§ 329 276 455 329 118 N 0 0 N N — 0 6 — —
Louisiana — 417 775 — 132 — 0 1 — — — 1 5 — —
Oklahoma — 157 392 — 232 N 0 0 N N — 1 16 — —
Texas§ — 1,947 2,343 — 1,419 N 0 0 N N — 2 140 — —
Mountain 889 1,264 1,804 889 828 71 86 182 71 90 — 8 37 — 4
Arizona 283 470 650 283 261 71 86 181 71 89 — 1 9 — 2
Colorado 279 238 579 279 207 N 0 0 N N — 1 12 — —
Idaho§ — 65 314 — 69 N 0 0 N N — 1 5 — 1
Montana§ 12 59 87 12 36 N 0 0 N N — 1 3 — —
Nevada§ 89 177 415 89 110 — 0 6 — 1 — 0 1 — —
New Mexico§ 194 130 455 194 85 — 0 3 — — — 1 23 — 1
Utah 6 107 253 6 60 — 0 3 — — — 0 6 — —
Wyoming§ 26 31 58 26 — — 0 1 — — — 0 4 — —
Pacific 1,200 3,663 4,231 1,200 2,377 32 32 159 32 217 1 8 18 1 3
Alaska 45 85 137 45 11 N 0 0 N N — 0 1 — —
California 866 2,875 3,301 866 1,876 32 32 159 32 217 — 5 14 — 1
Hawaii 5 103 161 5 56 N 0 0 N N — 0 1 — —
Oregon§ — 191 631 — 134 N 0 0 N N 1 1 4 1 2
Washington 284 356 634 284 300 N 0 0 N N — 1 11 — —
American Samoa — 0 20 — — N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 4 24 — — — 0 0 — — — 0 0 — —
Puerto Rico 53 116 333 53 — N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 13 23 — 6 — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Chlamydia refers to genital infections caused by Chlamydia trachomatis.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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Haemophilus influenzae, invasive 


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 84 304 588 84 183 2,302 5,909 6,818 2,302 4,312 30 46 81 30 58
New England 6 24 49 6 22 39 97 171 39 68 1 2 8 1 4
Connecticut — 6 14 — 7 — 50 129 — 14 — 0 7 — —
Maine§ 3 3 12 3 — 2 2 6 2 — 1 0 2 1 —
Massachusetts — 8 17 — 9 31 39 69 31 48 — 0 5 — 4
New Hampshire 2 3 11 2 2 1 2 6 1 — — 0 1 — —
Rhode Island§ — 1 8 — 1 4 6 13 4 6 — 0 7 — —
Vermont§ 1 3 13 1 3 1 0 3 1 — — 0 3 — —
Mid. Atlantic 12 60 108 12 32 129 621 988 129 319 7 10 18 7 6
New Jersey — 7 14 — 10 — 101 167 — 68 — 1 7 — 3
New York (Upstate) 8 21 51 8 1 53 117 274 53 — 2 3 7 2 —
New York City — 16 29 — 8 — 180 633 — 91 — 1 6 — 1
Pennsylvania 4 16 46 4 13 76 213 270 76 160 5 4 8 5 2
E.N. Central 20 48 88 20 50 402 1,197 1,650 402 1,287 4 7 17 4 10
Illinois — 11 31 — 18 12 361 482 12 320 — 2 6 — 7
Indiana N 0 0 N N 114 148 284 114 243 — 1 12 — —
Michigan 3 12 22 3 9 248 320 657 248 187 — 0 2 — —
Ohio 16 17 31 16 16 — 277 531 — 424 4 2 6 4 1
Wisconsin 1 9 20 1 7 28 83 176 28 113 — 0 2 — 2
W.N. Central 7 28 143 7 12 24 316 425 24 238 2 3 15 2 7
Iowa — 6 18 — 4 — 28 48 — 20 — 0 1 — 1
Kansas — 3 11 — 1 12 40 130 12 26 — 0 3 — —
Minnesota — 0 106 — — — 55 92 — 55 — 0 10 — —
Missouri 5 8 22 5 4 — 149 199 — 113 2 1 6 2 4
Nebraska§ 1 4 10 1 3 — 25 47 — 21 — 0 2 — 2
North Dakota — 0 3 — — — 2 6 — 3 — 0 3 — —
South Dakota 1 2 10 1 — 12 7 20 12 — — 0 0 — —
S. Atlantic 20 54 87 20 27 909 1,229 2,007 909 715 11 12 25 11 17
Delaware — 1 3 — 2 7 20 44 7 14 — 0 2 — —
District of Columbia — 1 5 — — 51 52 101 51 28 — 0 2 — —
Florida 18 24 57 18 13 383 447 522 383 318 8 3 9 8 —
Georgia — 9 27 — 8 3 165 442 3 37 — 2 9 — 9
Maryland§ 2 5 12 2 1 85 117 206 85 74 1 2 6 1 4
North Carolina N 0 0 N N — 0 831 — — 2 1 9 2 —
South Carolina§ — 2 6 — 1 265 185 829 265 114 — 1 7 — 1
Virginia§ — 7 17 — 2 113 182 486 113 123 — 1 6 — 2
West Virginia — 1 5 — — 2 14 26 2 7 — 0 3 — 1
E.S. Central 1 8 21 1 2 350 547 837 350 374 1 3 8 1 4
Alabama§ — 5 12 — 2 — 172 250 — 168 — 0 2 — 2
Kentucky N 0 0 N N 124 89 153 124 51 — 0 1 — —
Mississippi N 0 0 N N — 134 401 — 50 — 0 2 — 1
Tennessee§ 1 3 13 1 — 226 163 297 226 105 1 2 6 1 1
W.S. Central 3 7 20 3 1 86 944 1,297 86 703 — 2 8 — —
Arkansas§ — 2 8 — — 86 86 167 86 56 — 0 2 — —
Louisiana — 2 10 — — — 170 317 — 63 — 0 1 — —
Oklahoma 3 2 9 3 1 — 56 124 — 98 — 1 7 — —
Texas§ N 0 0 N N — 629 763 — 486 — 0 2 — —
Mountain 1 27 62 1 8 104 206 337 104 158 3 5 14 3 8
Arizona 1 2 8 1 2 43 64 93 43 51 2 2 11 2 1
Colorado — 10 27 — 1 34 57 99 34 38 — 1 5 — 2
Idaho§ — 3 14 — — — 3 13 — 6 — 0 4 — —
Montana§ — 1 9 — — — 2 7 — — — 0 1 — 1
Nevada§ — 1 8 — — 8 39 129 8 32 — 0 2 — 1
New Mexico§ — 1 7 — 3 19 23 47 19 28 — 0 4 — 3
Utah — 6 18 — 1 — 10 20 — 3 1 1 5 1 —
Wyoming§ — 0 3 — 1 — 2 9 — — — 0 2 — —
Pacific 14 53 85 14 29 259 595 759 259 450 1 2 6 1 2
Alaska 3 2 10 3 1 10 10 17 10 3 — 0 2 — —
California 9 34 56 9 21 201 497 633 201 363 — 0 3 — 1
Hawaii — 1 4 — 1 2 11 22 2 7 — 0 2 — —
Oregon§ 2 8 18 2 6 — 23 48 — 35 1 1 4 1 1
Washington — 8 34 — — 46 53 90 46 42 — 0 2 — —
American Samoa — 0 0 — — — 0 1 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 1 15 — — — 0 0 — —
Puerto Rico — 2 13 — — 1 5 25 1 — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 2 6 — — N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
Reporting area



















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 12 45 76 12 37 34 66 92 34 45 20 44 145 20 32
New England — 2 7 — 1 — 1 7 — — — 2 16 — 1
Connecticut — 0 4 — — — 0 7 — — — 0 5 — —
Maine§ — 0 2 — — — 0 2 — — — 0 2 — —
Massachusetts — 0 5 — 1 — 0 1 — — — 0 2 — —
New Hampshire — 0 2 — — — 0 2 — — — 0 5 — —
Rhode Island§ — 0 2 — — — 0 1 — — — 0 14 — —
Vermont§ — 0 1 — — — 0 1 — — — 0 1 — 1
Mid. Atlantic — 6 12 — 6 2 9 14 2 10 5 14 59 5 8
New Jersey — 1 4 — — — 2 7 — 5 — 1 8 — 1
New York (Upstate) — 1 4 — — — 1 6 — — 3 5 19 3 —
New York City — 2 6 — 3 — 2 6 — — — 2 12 — 2
Pennsylvania — 1 6 — 3 2 3 8 2 5 2 6 33 2 5
E.N. Central 3 6 16 3 5 13 8 13 13 8 7 8 40 7 11
Illinois — 2 10 — 1 — 2 6 — 3 — 1 10 — 3
Indiana — 0 4 — — — 1 4 — — 1 1 6 1 —
Michigan — 2 7 — 3 1 2 6 1 1 1 2 16 1 4
Ohio 3 1 4 3 1 12 2 8 12 3 5 3 18 5 4
Wisconsin — 0 2 — — — 0 1 — 1 — 0 3 — —
W.N. Central — 4 16 — 8 1 2 7 1 1 — 2 9 — —
Iowa — 1 7 — 4 — 0 2 — — — 0 2 — —
Kansas — 0 3 — 1 — 0 3 — — — 0 1 — —
Minnesota — 0 8 — — — 0 4 — — — 0 4 — —
Missouri — 1 3 — — 1 1 4 1 1 — 1 7 — —
Nebraska§ — 0 5 — 2 — 0 2 — — — 0 4 — —
North Dakota — 0 0 — — — 0 1 — — — 0 0 — —
South Dakota — 0 1 — 1 — 0 0 — — — 0 1 — —
S. Atlantic 6 7 14 6 5 9 17 34 9 13 4 8 22 4 7
Delaware — 0 1 — — — 0 3 — — — 0 2 — —
District of Columbia U 0 0 U U U 0 0 U U — 0 2 — 1
Florida 4 2 8 4 1 5 6 12 5 2 1 3 7 1 2
Georgia 1 1 4 1 1 4 3 8 4 3 — 0 4 — —
Maryland§ 1 1 3 1 2 — 2 4 — 2 3 2 10 3 4
North Carolina — 0 9 — — — 0 17 — — — 0 7 — —
South Carolina§ — 0 3 — — — 1 6 — 2 — 0 2 — —
Virginia§ — 1 5 — 1 — 2 7 — 1 — 1 4 — —
West Virginia — 0 1 — — — 1 4 — 3 — 0 3 — —
E.S. Central 1 1 9 1 1 2 7 13 2 2 2 2 10 2 3
Alabama§ — 0 2 — — — 2 6 — 1 — 0 2 — —
Kentucky — 0 3 — 1 — 2 5 — — 1 1 4 1 3
Mississippi — 0 2 — — 1 1 3 1 — — 0 1 — —
Tennessee§ 1 0 6 1 — 1 3 8 1 1 1 0 5 1 —
W.S. Central — 3 12 — — 2 12 23 2 1 — 1 9 — —
Arkansas§ — 0 1 — — — 0 4 — — — 0 2 — —
Louisiana — 0 1 — — — 1 4 — 1 — 0 2 — —
Oklahoma — 0 3 — — — 2 8 — — — 0 6 — —
Texas§ — 3 11 — — 2 8 19 2 — — 1 5 — —
Mountain 1 4 12 1 1 1 4 12 1 4 2 2 8 2 1
Arizona 1 2 11 1 1 — 1 5 — 1 2 0 2 2 1
Colorado — 0 3 — — — 0 3 — 2 — 0 2 — —
Idaho§ — 0 3 — — — 0 2 — — — 0 1 — —
Montana§ — 0 1 — — — 0 1 — — — 0 1 — —
Nevada§ — 0 3 — — — 0 3 — — — 0 2 — —
New Mexico§ — 0 3 — — — 0 2 — 1 — 0 1 — —
Utah — 0 2 — — 1 0 3 1 — — 0 2 — —
Wyoming§ — 0 1 — — — 0 1 — — — 0 0 — —
Pacific 1 10 24 1 10 4 7 17 4 6 — 4 10 — 1
Alaska — 0 1 — — 1 0 2 1 — — 0 1 — —
California 1 7 24 1 9 3 5 13 3 4 — 3 8 — 1
Hawaii — 0 2 — — — 0 1 — 1 — 0 1 — —
Oregon§ — 0 3 — 1 — 1 3 — 1 — 0 2 — —
Washington — 1 5 — — — 1 4 — — — 0 3 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 2 — — — 0 5 — 1 — 0 1 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for acute hepatitis C, viral are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 56 440 1,455 56 128 5 20 44 5 10 7 19 47 7 21
New England 1 43 260 1 23 — 0 6 — 1 — 0 3 — 1
Connecticut — 0 0 — — — 0 3 — — — 0 1 — —
Maine§ — 3 73 — — — 0 1 — — — 0 1 — —
Massachusetts — 11 114 — 16 — 0 2 — 1 — 0 3 — 1
New Hampshire — 13 141 — 7 — 0 2 — — — 0 0 — —
Rhode Island§ — 0 0 — — — 0 1 — — — 0 0 — —
Vermont§ 1 3 40 1 — — 0 1 — — — 0 0 — —
Mid. Atlantic 15 245 1,003 15 73 — 4 14 — 4 — 2 6 — 1
New Jersey — 31 211 — 27 — 0 0 — — — 0 2 — 1
New York (Upstate) 2 99 497 2 4 — 0 5 — — — 0 3 — —
New York City — 0 4 — 2 — 3 10 — 4 — 0 2 — —
Pennsylvania 13 84 531 13 40 — 1 3 — — — 1 5 — —
E.N. Central — 11 145 — 7 1 2 7 1 2 2 3 9 2 4
Illinois — 0 11 — — — 1 6 — 1 — 1 5 — 3
Indiana — 0 8 — — — 0 2 — — — 0 4 — —
Michigan — 1 10 — 1 — 0 2 — — — 0 3 — 1
Ohio — 1 5 — — 1 0 3 1 1 2 1 4 2 —
Wisconsin — 10 129 — 6 — 0 3 — — — 0 2 — —
W.N. Central — 8 156 — — — 1 10 — — — 2 8 — 1
Iowa — 1 8 — — — 0 3 — — — 0 3 — 1
Kansas — 0 1 — — — 0 2 — — — 0 2 — —
Minnesota — 4 152 — — — 0 8 — — — 0 7 — —
Missouri — 0 1 — — — 0 3 — — — 0 3 — —
Nebraska§ — 0 2 — — — 0 2 — — — 0 1 — —
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — — — 0 0 — — — 0 1 — —
S. Atlantic 35 66 219 35 23 1 5 15 1 1 3 2 10 3 3
Delaware 3 12 37 3 5 — 0 1 — — — 0 1 — —
District of Columbia — 2 11 — — — 0 2 — — — 0 0 — —
Florida 3 2 10 3 1 — 1 7 — — 1 1 3 1 2
Georgia — 0 3 — — — 1 5 — 1 — 0 2 — —
Maryland§ 29 29 158 29 13 — 1 7 — — — 0 4 — —
North Carolina — 0 7 — — 1 0 7 1 — 1 0 3 1 —
South Carolina§ — 0 2 — — — 0 1 — — — 0 3 — 1
Virginia§ — 13 52 — 4 — 1 3 — — 1 0 2 1 —
West Virginia — 1 11 — — — 0 0 — — — 0 1 — —
E.S. Central — 0 5 — — — 0 2 — — — 1 6 — 2
Alabama§ — 0 3 — — — 0 1 — — — 0 2 — —
Kentucky — 0 2 — — — 0 1 — — — 0 2 — 1
Mississippi — 0 1 — — — 0 1 — — — 0 2 — —
Tennessee§ — 0 3 — — — 0 2 — — — 0 3 — 1
W.S. Central — 2 8 — — — 1 11 — — — 2 7 — 2
Arkansas§ — 0 0 — — — 0 0 — — — 0 2 — —
Louisiana — 0 1 — — — 0 1 — — — 0 3 — 1
Oklahoma — 0 0 — — — 0 2 — — — 0 3 — 1
Texas§ — 2 8 — — — 1 11 — — — 1 5 — —
Mountain 1 0 4 1 — — 0 3 — 1 1 1 4 1 4
Arizona — 0 2 — — — 0 2 — — — 0 2 — —
Colorado — 0 1 — — — 0 1 — 1 — 0 1 — —
Idaho§ — 0 2 — — — 0 1 — — — 0 1 — —
Montana§ — 0 1 — — — 0 0 — — — 0 1 — —
Nevada§ — 0 2 — — — 0 3 — — 1 0 1 1 1
New Mexico§ — 0 2 — — — 0 1 — — — 0 1 — —
Utah 1 0 1 1 — — 0 1 — — — 0 1 — 3
Wyoming§ — 0 1 — — — 0 0 — — — 0 1 — —
Pacific 4 5 11 4 2 3 2 10 3 1 1 5 19 1 3
Alaska — 0 2 — — — 0 2 — — — 0 2 — —
California 4 3 10 4 2 2 2 8 2 — 1 3 19 1 2
Hawaii N 0 0 N N — 0 1 — — — 0 1 — —
Oregon§ — 1 4 — — 1 0 2 1 1 — 1 3 — 1
Washington — 0 4 — — — 0 3 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 2 — — — 0 0 — —
Puerto Rico N 0 0 N N 1 0 1 1 — — 0 1 — —
U.S. Virgin Islands N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
Reporting area
























2008Med Max Med Max Med Max
United States 89 182 351 89 96 19 102 168 19 37 2 31 145 2 5
New England — 11 32 — 35 — 7 20 — — — 0 2 — —
Connecticut — 0 4 — 3 — 4 17 — — — 0 0 — —
Maine† — 0 5 — — — 1 5 — — N 0 0 N N
Massachusetts — 7 24 — 32 N 0 0 N N — 0 1 — —
New Hampshire — 1 4 — — — 0 3 — — — 0 1 — —
Rhode Island† — 1 7 — — N 0 0 N N — 0 2 — —
Vermont† — 0 2 — — — 1 6 — — — 0 0 — —
Mid. Atlantic 5 20 42 5 7 4 33 67 4 12 — 1 5 — 2
New Jersey — 1 6 — 2 — 0 0 — — — 0 2 — 1
New York (Upstate) 1 7 24 1 — 4 9 20 4 8 — 0 2 — —
New York City — 0 5 — 2 — 0 2 — 1 — 0 2 — 1
Pennsylvania 4 8 35 4 3 — 21 52 — 3 — 0 2 — —
E.N. Central 29 31 189 29 19 1 3 28 1 1 — 1 15 — —
Illinois — 6 43 — 1 1 1 21 1 1 — 1 10 — —
Indiana 1 1 27 1 — — 0 2 — — — 0 3 — —
Michigan 2 6 14 2 1 — 0 8 — — — 0 1 — —
Ohio 26 10 176 26 15 — 1 7 — — — 0 4 — —
Wisconsin — 2 7 — 2 N 0 0 N N — 0 1 — —
W.N. Central 30 17 120 30 9 — 3 13 — — — 4 32 — 1
Iowa — 2 20 — 5 — 0 5 — — — 0 2 — —
Kansas — 1 13 — — — 0 0 — — — 0 0 — —
Minnesota — 2 26 — — — 0 10 — — — 0 0 — —
Missouri 28 6 50 28 2 — 1 8 — — — 4 31 — 1
Nebraska† 2 2 35 2 1 — 0 0 — — — 0 4 — —
North Dakota — 0 1 — — — 0 7 — — — 0 0 — —
South Dakota — 0 7 — 1 — 0 2 — — — 0 1 — —
S. Atlantic 16 17 44 16 7 11 37 101 11 21 2 12 71 2 1
Delaware — 0 3 — — — 0 0 — — — 0 5 — —
District of Columbia — 0 1 — 1 — 0 0 — — — 0 2 — —
Florida 7 5 20 7 1 7 0 77 7 — — 0 3 — —
Georgia — 1 7 — 1 — 5 42 — 4 — 1 8 — —
Maryland† 5 2 8 5 3 — 8 17 — 8 — 1 7 — 1
North Carolina — 0 15 — — 4 9 16 4 7 2 3 55 2 —
South Carolina† 4 2 11 4 — — 0 0 — — — 1 9 — —
Virginia† — 3 10 — 1 — 11 24 — 2 — 2 15 — —
West Virginia — 0 2 — — — 1 9 — — — 0 1 — —
E.S. Central 3 7 28 3 7 — 3 7 — — — 3 23 — —
Alabama† — 1 5 — 2 — 0 0 — — — 1 8 — —
Kentucky 2 2 11 2 — — 0 4 — — — 0 1 — —
Mississippi — 2 5 — 5 — 0 1 — — — 0 3 — —
Tennessee† 1 1 14 1 — — 2 6 — — — 2 19 — —
W.S. Central 1 28 113 1 — — 1 11 — — — 1 41 — —
Arkansas† — 1 19 — — — 0 6 — — — 0 14 — —
Louisiana — 1 7 — — — 0 0 — — — 0 1 — —
Oklahoma — 0 21 — — — 0 10 — — — 0 26 — —
Texas† 1 26 108 1 — — 0 1 — — — 1 6 — —
Mountain 2 15 34 2 8 — 1 8 — 2 — 1 3 — 1
Arizona — 4 10 — 1 N 0 0 N N — 0 2 — —
Colorado — 3 7 — 6 — 0 0 — — — 0 1 — —
Idaho† 1 0 5 1 — — 0 0 — — — 0 1 — —
Montana† — 1 11 — — — 0 2 — — — 0 1 — —
Nevada† — 0 7 — 1 — 0 4 — — — 0 2 — —
New Mexico† — 1 8 — — — 0 3 — 2 — 0 1 — 1
Utah 1 4 17 1 — — 0 6 — — — 0 1 — —
Wyoming† — 0 2 — — — 0 3 — — — 0 2 — —
Pacific 3 25 83 3 4 3 3 13 3 1 — 0 1 — —
Alaska 3 3 21 3 — 2 0 4 2 — N 0 0 N N
California — 8 23 — — 1 3 12 1 1 — 0 1 — —
Hawaii — 0 2 — — — 0 0 — — N 0 0 N N
Oregon† — 3 10 — 4 — 0 4 — — — 0 1 — —
Washington — 6 63 — — — 0 0 — — N 0 0 N N
American Samoa — 0 0 — — N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — N 0 0 N N
Puerto Rico — 0 0 — — — 1 5 — — N 0 0 N N
U.S. Virgin Islands — 0 0 — — N 0 0 N N N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
Reporting area


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 336 839 1,493 336 883 28 82 251 28 72 187 421 609 187 244
New England 1 19 63 1 513 — 3 14 — 47 — 2 7 — 39
Connecticut — 0 0 — 484 — 0 0 — 44 — 0 0 — 38
Maine§ — 3 8 — — — 0 3 — 1 — 0 6 — —
Massachusetts — 14 52 — 23 — 1 11 — 2 — 1 5 — 1
New Hampshire — 2 10 — 4 — 1 3 — — — 0 1 — —
Rhode Island§ — 2 9 — 1 — 0 3 — — — 0 1 — —
Vermont§ 1 1 7 1 1 — 0 3 — — — 0 2 — —
Mid. Atlantic 13 88 177 13 48 1 6 192 1 2 6 44 96 6 24
New Jersey — 13 30 — 15 — 0 3 — 1 — 12 38 — 14
New York (Upstate) 5 26 60 5 3 1 3 188 1 — — 10 35 — —
New York City — 23 53 — 10 — 1 5 — — — 13 35 — 5
Pennsylvania 8 27 78 8 20 — 1 8 — 1 6 3 23 6 5
E.N. Central 31 91 193 31 76 1 11 74 1 9 41 78 121 41 44
Illinois — 26 72 — 25 — 1 10 — — — 19 34 — 16
Indiana — 9 53 — — — 1 14 — — 1 10 39 1 5
Michigan 3 17 38 3 12 — 2 43 — 4 — 3 20 — 1
Ohio 28 26 65 28 24 1 3 17 1 — 40 40 80 40 17
Wisconsin — 14 50 — 15 — 4 20 — 5 — 8 33 — 5
W.N. Central 19 49 151 19 13 2 12 59 2 3 2 16 39 2 5
Iowa — 8 16 — 4 — 2 21 — 3 — 3 11 — —
Kansas 3 7 31 3 1 1 1 7 1 — 1 1 5 1 —
Minnesota — 13 70 — — — 3 21 — — — 5 25 — —
Missouri 13 14 48 13 7 1 2 11 1 — 1 3 14 1 4
Nebraska§ 2 4 13 2 1 — 2 29 — — — 0 3 — —
North Dakota — 0 7 — — — 0 1 — — — 0 5 — —
South Dakota 1 2 9 1 — — 1 4 — — — 0 9 — 1
S. Atlantic 191 241 457 191 113 19 13 50 19 7 54 58 100 54 48
Delaware — 2 9 — — — 0 2 — 1 — 0 1 — —
District of Columbia — 1 4 — 1 — 0 1 — 1 — 0 3 — —
Florida 68 100 174 68 68 7 2 11 7 4 12 14 34 12 26
Georgia 18 42 86 18 13 — 1 7 — — 10 20 48 10 14
Maryland§ 8 13 36 8 10 3 2 10 3 — 5 2 8 5 1
North Carolina 92 23 106 92 — 9 1 19 9 — 26 3 27 26 —
South Carolina§ 5 18 55 5 6 — 1 4 — — 1 9 32 1 6
Virginia§ — 18 42 — 3 — 3 25 — — — 4 26 — 1
West Virginia — 3 6 — 12 — 0 3 — 1 — 0 3 — —
E.S. Central 14 58 138 14 34 — 5 21 — 4 6 35 67 6 47
Alabama§ — 14 47 — 15 — 1 17 — 2 — 7 18 — 14
Kentucky 8 9 18 8 7 — 1 7 — 1 1 3 24 1 7
Mississippi — 14 57 — 7 — 0 2 — — — 5 18 — 17
Tennessee§ 6 14 60 6 5 — 2 7 — 1 5 17 44 5 9
W.S. Central 1 128 265 1 9 — 6 27 — — 51 92 215 51 5
Arkansas§ — 11 40 — — — 1 3 — — — 11 27 — —
Louisiana — 17 50 — 6 — 0 1 — — — 11 25 — 4
Oklahoma 1 14 36 1 — — 1 19 — — — 3 11 — —
Texas§ — 91 179 — 3 — 5 12 — — 51 62 188 51 1
Mountain 11 59 110 11 34 — 10 39 — — 18 20 53 18 13
Arizona 6 19 45 6 12 — 1 5 — — 14 10 34 14 9
Colorado — 12 43 — 5 — 3 18 — — — 2 11 — 1
Idaho§ 2 3 14 2 2 — 2 15 — — — 0 2 — —
Montana§ — 2 8 — — — 0 3 — — — 0 1 — —
Nevada§ 3 3 9 3 5 — 0 2 — — 4 4 13 4 —
New Mexico§ — 6 33 — 7 — 1 6 — — — 1 10 — 2
Utah — 6 19 — — — 1 9 — — — 1 3 — —
Wyoming§ — 1 4 — 3 — 0 1 — — — 0 1 — 1
Pacific 55 112 523 55 43 5 10 48 5 — 9 29 82 9 19
Alaska 1 1 4 1 1 — 0 1 — — — 0 1 — —
California 44 81 507 44 28 5 6 39 5 — 7 26 74 7 14
Hawaii 8 4 15 8 5 — 0 2 — — — 1 3 — 2
Oregon§ 2 7 20 2 9 — 1 8 — — 2 1 10 2 3
Washington — 12 71 — — — 2 15 — — — 2 9 — —
American Samoa — 0 1 — — — 0 0 — — — 0 0 — 1
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 — — — 0 0 — — — 0 3 — —
Puerto Rico — 10 29 — 6 — 0 1 — — — 0 4 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
Vol. 58 / No. 1 MMWR 19
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
Reporting area
Streptococcal diseases, invasive, group A












52 weeks Cum  
2009
Cum  
2008Med Max Med Max
United States 63 87 181 63 89 15 33 55 15 33
New England — 5 31 — 9 — 1 11 — 2
Connecticut — 0 26 — — — 0 11 — —
Maine§ — 0 3 — — — 0 1 — —
Massachusetts — 2 8 — 7 — 0 5 — 1
New Hampshire — 0 2 — 2 — 0 1 — 1
Rhode Island§ — 0 9 — — — 0 2 — —
Vermont§  — 0 3 — — — 0 1 — —
Mid. Atlantic 4 18 43 4 14 1 3 12 1 6
New Jersey — 2 11 — 3 — 1 4 — 3
New York (Upstate) 1 6 17 1 1 1 2 11 1 —
New York City — 4 10 — 4 — 0 6 — 3
Pennsylvania 3 7 16 3 6 N 0 0 N N
E.N. Central 9 15 42 9 10 5 5 15 5 9
Illinois — 4 16 — 4 — 1 5 — 3
Indiana — 2 9 — 1 — 0 5 — —
Michigan — 3 10 — 2 1 1 5 1 4
Ohio 9 5 14 9 3 4 1 4 4 1
Wisconsin — 1 10 — — — 1 4 — 1
W.N. Central 5 5 39 5 2 2 2 11 2 4
Iowa — 0 0 — — — 0 0 — —
Kansas 1 0 5 1 — 1 0 3 1 —
Minnesota — 0 35 — — — 0 9 — —
Missouri 2 2 10 2 2 1 1 2 1 2
Nebraska§ 2 1 3 2 — — 0 1 — 2
North Dakota — 0 3 — — — 0 2 — —
South Dakota — 0 2 — — — 0 1 — —
S. Atlantic 28 21 37 28 28 7 6 16 7 4
Delaware — 0 2 — — — 0 0 — —
District of Columbia — 0 4 — 2 — 0 1 — —
Florida 9 5 10 9 5 2 1 4 2 —
Georgia 9 4 14 9 8 2 1 4 2 —
Maryland§ 5 4 8 5 6 3 1 5 3 2
North Carolina 3 2 10 3 — N 0 0 N N
South Carolina§ 1 1 4 1 5 — 1 5 — 2
Virginia§ 1 3 9 1 1 — 0 6 — —
West Virginia — 0 3 — 1 — 0 1 — —
E.S. Central 2 3 9 2 1 — 2 6 — —
Alabama§ N 0 0 N N N 0 0 N N
Kentucky — 1 3 — — N 0 0 N N
Mississippi N 0 0 N N — 0 3 — —
Tennessee§ 2 3 6 2 1 — 1 5 — —
W.S. Central 8 9 27 8 2 — 5 13 — 1
Arkansas§ — 0 2 — — — 0 2 — —
Louisiana — 0 2 — 1 — 0 2 — 1
Oklahoma 7 2 8 7 1 — 1 3 — —
Texas§ 1 6 20 1 — — 3 13 — —
Mountain 2 10 20 2 22 — 4 13 — 7
Arizona 2 3 9 2 7 — 2 8 — 4
Colorado — 2 8 — 6 — 1 4 — 3
Idaho§ — 0 2 — — — 0 1 — —
Montana§ N 0 0 N N — 0 1 — —
Nevada§ — 0 1 — 1 N 0 0 N N
New Mexico§ — 1 8 — 7 — 0 3 — —
Utah — 1 4 — 1 — 0 4 — —
Wyoming§ — 0 2 — — — 0 1 — —
Pacific 5 3 8 5 1 — 0 2 — —
Alaska 1 1 4 1 — N 0 0 N N
California — 0 0 — — N 0 0 N N
Hawaii 4 2 8 4 1 — 0 2 — —
Oregon§ N 0 0 N N N 0 0 N N
Washington N 0 0 N N N 0 0 N N
American Samoa — 0 12 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by S. pneumoniae, which is susceptible or for which susceptibility testing is not available 
(NNDSS event code 11717).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
Reporting area
Streptococcus pneumoniae, invasive disease, drug resistant†


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 64 54 105 64 89 4 8 23 4 10 97 238 300 97 164
New England 1 1 48 1 2 — 0 5 — — 3 5 14 3 4
Connecticut — 0 48 — — — 0 5 — — — 0 3 — —
Maine§ — 0 2 — 1 — 0 1 — — — 0 2 — —
Massachusetts — 0 0 — — — 0 0 — — 3 4 11 3 2
New Hampshire — 0 0 — — — 0 0 — — — 0 2 — 1
Rhode Island§ — 0 2 — — — 0 1 — — — 0 5 — 1
Vermont§ 1 0 2 1 1 — 0 1 — — — 0 2 — —
Mid. Atlantic — 4 13 — 7 — 0 2 — — 4 33 53 4 21
New Jersey — 0 0 — — — 0 0 — — — 4 10 — 1
New York (Upstate) — 1 4 — — — 0 1 — — — 3 7 — —
New York City — 1 6 — 1 — 0 0 — — — 20 36 — 17
Pennsylvania — 1 9 — 6 — 0 2 — — 4 5 12 4 3
E.N. Central 18 12 41 18 25 1 2 7 1 3 17 22 37 17 33
Illinois — 0 10 — 16 — 0 2 — 3 1 7 17 1 13
Indiana — 2 31 — — — 0 5 — — 1 3 10 1 1
Michigan 1 0 3 1 1 — 0 1 — — 4 2 21 4 10
Ohio 17 7 17 17 8 1 1 4 1 — 10 6 15 10 8
Wisconsin — 0 0 — — — 0 0 — — 1 1 4 1 1
W.N. Central 3 2 9 3 10 — 0 2 — 1 — 8 14 — 7
Iowa — 0 0 — — — 0 0 — — — 0 2 — —
Kansas — 1 5 — 5 — 0 1 — 1 — 0 5 — —
Minnesota — 0 0 — — — 0 0 — — — 2 5 — 1
Missouri 3 1 8 3 5 — 0 1 — — — 4 10 — 6
Nebraska§ — 0 0 — — — 0 0 — — — 0 1 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 1 — — — 0 1 — — — 0 1 — —
S. Atlantic 30 21 53 30 35 2 3 13 2 4 47 52 104 47 12
Delaware — 0 1 — — — 0 0 — — — 0 4 — —
District of Columbia — 0 3 — — — 0 1 — — 8 2 9 8 —
Florida 23 13 30 23 20 2 3 12 2 2 13 19 37 13 9
Georgia 6 6 23 6 12 — 1 5 — 2 — 12 33 — 1
Maryland§ 1 0 2 1 — — 0 1 — — 4 6 14 4 1
North Carolina N 0 0 N N N 0 0 N N 18 5 19 18 —
South Carolina§ — 0 0 — — — 0 0 — — 1 2 6 1 —
Virginia§ N 0 0 N N N 0 0 N N 3 5 16 3 1
West Virginia — 1 9 — 3 — 0 2 — — — 0 1 — —
E.S. Central 10 5 19 10 8 1 1 4 1 — 13 21 37 13 16
Alabama§ N 0 0 N N N 0 0 N N — 8 17 — 7
Kentucky 5 1 6 5 3 1 0 2 1 — 1 1 10 1 3
Mississippi — 0 2 — — — 0 1 — — — 3 19 — —
Tennessee§ 5 3 17 5 5 — 1 3 — — 12 8 19 12 6
W.S. Central 2 2 7 2 2 — 0 2 — 2 5 41 63 5 31
Arkansas§ 2 0 4 2 — — 0 1 — — 5 2 19 5 1
Louisiana — 1 6 — 2 — 0 1 — 2 — 10 31 — 2
Oklahoma N 0 0 N N N 0 0 N N — 1 5 — 5
Texas§ — 0 0 — — — 0 0 — — — 26 47 — 23
Mountain — 2 14 — — — 0 4 — — 3 9 16 3 6
Arizona — 0 0 — — — 0 0 — — — 5 13 — 2
Colorado — 0 0 — — — 0 0 — — 1 2 7 1 —
Idaho§ N 0 1 N N N 0 1 N N — 0 2 — —
Montana§ — 0 1 — — — 0 0 — — — 0 7 — —
Nevada§ N 0 1 N N N 0 0 N N — 1 6 — 1
New Mexico§ — 0 1 — — — 0 0 — — 2 1 4 2 3
Utah — 2 13 — — — 0 4 — — — 0 2 — —
Wyoming§ — 0 1 — — — 0 0 — — — 0 1 — —
Pacific — 0 1 — — — 0 1 — — 5 44 64 5 34
Alaska N 0 0 N N N 0 0 N N — 0 1 — —
California N 0 0 N N N 0 0 N N 3 40 58 3 26
Hawaii — 0 1 — — — 0 1 — — — 0 2 — 1
Oregon§ N 0 0 N N N 0 0 N N — 0 3 — 2
Washington N 0 0 N N N 0 0 N N 2 3 9 2 5
American Samoa N 0 0 N N N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 3 11 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Includes cases of invasive pneumococcal disease caused by drug-resistant S. pneumoniae (DRSP) (NNDSS event code 11720).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 10, 2009, and January 5, 2008  
(1st week)*
West Nile virus disease†
Reporting area


















52 weeks Cum 
2009
Cum 
2008Med Max Med Max Med Max
United States 173 508 1,001 173 310 — 1 76 — — — 1 73 — —
New England 8 11 22 8 11 — 0 2 — — — 0 1 — —
Connecticut — 0 0 — — — 0 2 — — — 0 1 — —
Maine¶ — 0 0 — — — 0 0 — — — 0 0 — —
Massachusetts — 0 1 — — — 0 0 — — — 0 0 — —
New Hampshire 6 5 13 6 7 — 0 0 — — — 0 0 — —
Rhode Island¶ — 0 0 — — — 0 1 — — — 0 0 — —
Vermont¶ 2 5 17 2 4 — 0 0 — — — 0 0 — —
Mid. Atlantic 2 45 81 2 51 — 0 8 — — — 0 5 — —
New Jersey N 0 0 N N — 0 1 — — — 0 1 — —
New York (Upstate) N 0 0 N N — 0 5 — — — 0 2 — —
New York City N 0 0 N N — 0 2 — — — 0 2 — —
Pennsylvania 2 45 81 2 51 — 0 2 — — — 0 1 — —
E.N. Central 62 138 312 62 95 — 0 8 — — — 0 3 — —
Illinois 4 23 64 4 7 — 0 4 — — — 0 2 — —
Indiana — 0 0 — — — 0 1 — — — 0 1 — —
Michigan 9 58 116 9 30 — 0 4 — — — 0 2 — —
Ohio 48 46 106 48 58 — 0 3 — — — 0 1 — —
Wisconsin 1 4 50 1 — — 0 2 — — — 0 1 — —
W.N. Central 22 21 71 22 11 — 0 6 — — — 0 21 — —
Iowa N 0 0 N N — 0 2 — — — 0 1 — —
Kansas 2 6 40 2 3 — 0 2 — — — 0 5 — —
Minnesota — 0 0 — — — 0 2 — — — 0 4 — —
Missouri 20 10 51 20 8 — 0 3 — — — 0 1 — —
Nebraska¶ N 0 0 N N — 0 1 — — — 0 8 — —
North Dakota — 0 39 — — — 0 2 — — — 0 11 — —
South Dakota — 0 5 — — — 0 5 — — — 0 6 — —
S. Atlantic 24 86 173 24 89 — 0 3 — — — 0 3 — —
Delaware — 1 5 — — — 0 0 — — — 0 1 — —
District of Columbia — 0 3 — 2 — 0 0 — — — 0 0 — —
Florida 21 29 87 21 17 — 0 2 — — — 0 0 — —
Georgia N 0 0 N N — 0 1 — — — 0 1 — —
Maryland¶ N 0 0 N N — 0 2 — — — 0 2 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina¶ 1 14 67 1 9 — 0 0 — — — 0 1 — —
Virginia¶ — 21 81 — 25 — 0 0 — — — 0 1 — —
West Virginia 2 12 33 2 36 — 0 1 — — — 0 0 — —
E.S. Central 4 17 101 4 13 — 0 7 — — — 0 8 — —
Alabama¶ 4 17 101 4 13 — 0 3 — — — 0 3 — —
Kentucky N 0 0 N N — 0 1 — — — 0 0 — —
Mississippi — 0 2 — — — 0 4 — — — 0 7 — —
Tennessee¶ N 0 0 N N — 0 1 — — — 0 3 — —
W.S. Central 47 113 435 47 10 — 0 8 — — — 0 7 — —
Arkansas¶ — 9 52 — — — 0 1 — — — 0 1 — —
Louisiana 1 1 10 1 1 — 0 3 — — — 0 5 — —
Oklahoma N 0 0 N N — 0 1 — — — 0 1 — —
Texas¶ 46 99 422 46 9 — 0 6 — — — 0 4 — —
Mountain — 40 90 — 28 — 0 12 — — — 0 22 — —
Arizona — 0 0 — — — 0 10 — — — 0 8 — —
Colorado — 14 44 — 7 — 0 4 — — — 0 10 — —
Idaho¶ N 0 0 N N — 0 1 — — — 0 6 — —
Montana¶ — 5 27 — 6 — 0 0 — — — 0 2 — —
Nevada¶ N 0 0 N N — 0 2 — — — 0 3 — —
New Mexico¶ — 3 18 — 5 — 0 2 — — — 0 1 — —
Utah — 12 55 — 9 — 0 2 — — — 0 5 — —
Wyoming¶ — 0 4 — 1 — 0 0 — — — 0 2 — —
Pacific 4 2 8 4 2 — 0 38 — — — 0 24 — —
Alaska 4 1 6 4 1 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 37 — — — 0 19 — —
Hawaii — 1 5 — 1 — 0 0 — — — 0 0 — —
Oregon¶ N 0 0 N N — 0 2 — — — 0 4 — —
Washington N 0 0 N N — 0 1 — — — 0 1 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 1 17 — — — 0 0 — — — 0 0 — —
Puerto Rico — 7 20 — 4 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.     —: No reported cases.     N: Not notifiable.     Cum: Cumulative year-to-date counts.     Med: Median.     Max: Maximum. 
* Incidence data for reporting year 2008 and 2009 are provisional. 
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). 
Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and 
influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 
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TABLE III. Deaths in 122 U.S. cities,* week ending January 10, 2009 (1st week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages >65 45–64 25–44 1–24 <1
All 
Ages >65 45–64 25–44 1–24 <1
New England 614 452 118 28 6 10 67 S. Atlantic 1,534 992 382 96 29 33 102
Boston, MA 171 116 43 5 3 4 19 Atlanta, GA 119 73 29 14 2 1 8
Bridgeport, CT 11 9 1 1 — — 1 Baltimore, MD 140 92 34 8 3 3 25
Cambridge, MA 16 12 3 — 1 — 2 Charlotte, NC 140 104 25 8 2 1 5
Fall River, MA 50 42 6 1 — 1 5 Jacksonville, FL 260 166 59 17 9 8 16
Hartford, CT 57 38 14 4 — 1 6 Miami, FL 95 53 28 5 3 5 9
Lowell, MA 31 27 4 — — — 5 Norfolk, VA 75 51 17 4 2 1 1
Lynn, MA 12 7 5 — — — 3 Richmond, VA 69 43 23 1 1 1 6
New Bedford, MA 31 28 1 1 — 1 2 Savannah, GA 74 43 23 6 2 — 8
New Haven, CT U U U U U U U St. Petersburg, FL 78 49 21 7 — 1 6
Providence, RI 72 52 13 5 1 1 6 Tampa, FL 360 252 78 18 5 7 14
Somerville, MA 4 1 1 2 — — — Washington, D.C. 103 55 37 7 — 4 2
Springfield, MA 43 31 7 4 — 1 6 Wilmington, DE 21 11 8 1 — 1 2
Waterbury, CT 40 27 8 4 1 — 5 E.S. Central 978 662 215 53 26 22 69
Worcester, MA 76 62 12 1 — 1 7 Birmingham, AL 151 105 34 5 3 4 17
Mid. Atlantic 2,639 1,832 586 145 45 31 152 Chattanooga, TN 117 86 23 3 1 4 6
Albany, NY 51 32 15 4 — — 3 Knoxville, TN 140 104 31 5 — — 10
Allentown, PA 34 25 9 — — — — Lexington, KY 65 39 18 7 — 1 4
Buffalo, NY 97 61 29 4 2 1 12 Memphis, TN 136 81 33 10 7 5 7
Camden, NJ 26 9 12 2 1 2 1 Mobile, AL 71 52 10 4 5 — 5
Elizabeth, NJ 19 14 3 2 — — — Montgomery, AL 73 42 21 7 2 1 5
Erie, PA 69 55 11 2 1 — 3 Nashville, TN 225 153 45 12 8 7 15
Jersey City, NJ 35 26 8 1 — — 2 W.S. Central 1,847 1,158 485 136 33 34 88
New York City, NY 1,416 987 308 86 23 12 63 Austin, TX 137 82 40 6 5 4 8
Newark, NJ 38 19 10 6 2 1 1 Baton Rouge, LA 35 27 5 3 — — —
Paterson, NJ 10 4 5 1 — — 3 Corpus Christi, TX U U U U U U U
Philadelphia, PA 315 191 81 27 10 6 15 Dallas, TX 238 152 50 21 3 11 16
Pittsburgh, PA§ 44 32 11 — — 1 7 El Paso, TX 169 114 41 14 — — 10
Reading, PA 37 27 7 2 — 1 4 Fort Worth, TX 209 140 57 5 2 5 3
Rochester, NY 163 132 23 4 1 3 18 Houston, TX 440 252 128 39 13 8 15
Schenectady, NY 26 24 2 — — — 3 Little Rock, AR 118 66 34 14 2 2 2
Scranton, PA 32 28 4 — — — 1 New Orleans, LA U U U U U U U
Syracuse, NY 151 108 34 2 4 3 14 San Antonio, TX 263 179 63 17 3 1 24
Trenton, NJ 36 28 5 2 — 1 1 Shreveport, LA 60 38 18 4 — — 3
Utica, NY 21 16 5 — — — — Tulsa, OK 178 108 49 13 5 3 7
Yonkers, NY 19 14 4 — 1 — 1 Mountain 1,092 732 215 100 27 18 81
E.N. Central 2,820 1,882 649 164 63 62 181 Albuquerque, NM U U U U U U U
Akron, OH 84 53 23 7 1 — 5 Boise, ID 56 38 10 4 1 3 3
Canton, OH 35 26 8 1 — — 4 Colorado Springs, CO 43 26 11 4 1 1 2
Chicago, IL 341 196 100 30 13 2 24 Denver, CO 84 57 18 7 2 — 6
Cincinnati, OH 125 83 22 8 1 11 7 Las Vegas, NV 298 189 66 31 9 3 22
Cleveland, OH 301 219 57 14 4 7 9 Ogden, UT 51 41 7 2 1 — 2
Columbus, OH 313 202 80 17 6 8 29 Phoenix, AZ 166 100 31 25 6 4 14
Dayton, OH 190 136 37 13 3 1 12 Pueblo, CO 46 31 10 3 1 1 2
Detroit, MI 259 133 77 28 12 9 15 Salt Lake City, UT 147 105 23 13 3 3 7
Evansville, IN 75 49 18 6 2 — 5 Tucson, AZ 201 145 39 11 3 3 23
Fort Wayne, IN 92 66 22 1 1 2 5 Pacific 2,146 1,534 434 108 49 21 196
Gary, IN 22 12 7 1 2 — 1 Berkeley, CA 22 15 6 — — 1 4
Grand Rapids, MI 73 54 11 4 1 3 7 Fresno, CA 69 51 12 4 1 1 4
Indianapolis, IN 270 180 60 11 10 9 20 Glendale, CA 54 44 7 2 — 1 10
Lansing, MI 71 54 11 3 — 3 5 Honolulu, HI 105 83 18 4 — — 11
Milwaukee, WI 147 102 37 8 — — 10 Long Beach, CA 91 60 17 9 3 2 9
Peoria, IL 60 50 10 — — — 9 Los Angeles, CA 313 209 71 22 7 4 34
Rockford, IL 59 44 9 3 1 2 2 Pasadena, CA 24 14 8 — — 2 2
South Bend, IN 97 68 19 3 4 3 3 Portland, OR 179 122 41 9 4 3 11
Toledo, OH 116 84 24 5 1 2 9 Sacramento, CA 132 101 25 4 2 — 14
Youngstown, OH 90 71 17 1 1 — — San Diego, CA 242 169 49 14 8 2 17
W.N. Central 663 440 151 33 19 20 51 San Francisco, CA 156 111 35 5 3 2 15
Des Moines, IA 44 32 12 — — — 3 San Jose, CA 252 183 47 15 6 1 31
Duluth, MN 41 33 6 1 1 — 3 Santa Cruz, CA 49 36 10 2 1 — 6
Kansas City, KS 34 18 11 2 2 1 3 Seattle, WA 202 147 36 12 6 1 10
Kansas City, MO 95 65 16 5 4 5 7 Spokane, WA 81 64 12 2 2 1 10
Lincoln, NE 54 41 9 3 — 1 5 Tacoma, WA 175 125 40 4 6 — 8
Minneapolis, MN 79 48 19 4 2 6 3 Total¶ 14,333 9,684 3,235 863 297 251 987
Omaha, NE 105 74 20 6 5 — 11
St. Louis, MO 69 36 23 5 2 3 5
St. Paul, MN 70 49 15 3 1 2 6
Wichita, KS 72 44 20 4 2 2 5
U: Unavailable.     —:No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its 
occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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TABLE IV. Provisional cases of selected notifiable disease,* United 
States, quarter ending January 3, 2009 (53rd week)
Reporting area








United States 2,218 2,096 2,797 9,795 12,859
New England 19 19 46 144 186
Connecticut 9 9 33 90 108
Maine 2 1 3 8 19
Massachusetts — 0 0 — —
New Hampshire 5 2 5 16 11
Rhode Island 3 3 8 26 45
Vermont — 0 2 4 3
Mid. Atlantic 544 410 544 1,976 1,918
New Jersey 106 69 106 380 467
New York (Upstate) 64 54 89 271 261
New York City 243 196 253 938 914
Pennsylvania 131 66 131 387 276
E.N. Central 223 154 228 806 1,196
Illinois 136 46 136 363 521
Indiana 26 26 37 118 128
Michigan — 0 20 52 226
Ohio 49 49 58 212 251
Wisconsin 12 10 20 61 70
W.N. Central 88 86 101 376 498
Iowa — 0 15 34 43
Kansas — 0 0 — 53
Minnesota 62 35 62 189 238
Missouri 16 16 40 105 119
Nebraska 8 3 14 32 25
North Dakota — 0 0 — 7
South Dakota 2 2 9 16 13
S. Atlantic 311 311 473 1,576 2,621
Delaware — 0 7 12 20
District of Columbia 6 6 16 49 60
Florida 130 130 229 723 989
Georgia 9 9 98 247 385
Maryland 68 50 73 263 271
North Carolina — 0 0 — 345
South Carolina — 0 0 — 218
Virginia 87 34 87 254 309
West Virginia 11 4 11 28 24
E.S. Central 151 97 189 606 666
Alabama 45 32 46 169 175
Kentucky 18 4 30 80 120
Mississippi 32 17 32 99 137
Tennessee 56 44 85 258 234
W.S. Central 185 185 416 1,341 1,982
Arkansas 22 8 22 72 106
Louisiana — 0 0 — 218
Oklahoma 24 18 28 94 148
Texas 139 139 376 1,175 1,510
Mountain 80 80 94 348 603
Arizona 53 43 61 212 301
Colorado 1 0 1 3 109
Idaho — 0 0 — —
Montana — 0 0 — —
Nevada — 0 29 50 101
New Mexico 19 10 19 58 51
Utah 7 5 8 25 41
Wyoming — 0 0 — —
Pacific 617 485 779 2,622 3,189
Alaska 12 9 13 44 51
California 564 449 730 2,378 2,725
Hawaii 27 22 39 118 122
Oregon — 0 0 — —
Washington 14 1 58 82 291
American Samoa — 0 0 — 3
C.N.M.I. — — — — —
Guam — 0 0 — —
Puerto Rico 9 8 18 51 98
U.S. Virgin Islands — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.                   —: No reported cases.  N: Not notifiable.
Cum: Cumulative year-to-date counts.       Med: Median. Max: Maximum.
* AIDS and HIV/AIDS data are not updated for this quarter because of upgrading 
of the national HIV/AIDS surveillance data management system.
 MMWR 
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free 
of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read 
SUBscribe mmwr-toc. Electronic copy also is available from CDC’s Internet server at http://www.cdc.gov/mmwr or from CDC’s file transfer protocol server at 
ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, 
Washington, DC 20402; telephone 202-512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business 
on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for 
Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the MMWR Series, including material to 
be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. 
All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations 
or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses 
listed in MMWR were current as of the date of publication.
24  January 16, 2009
U.S. Government Printing Office: 2009-523-019/41149 Region IV ISSN: 0149-2195
